NAUT · Nautilus Biotechnology, Inc. · Webcasts, Transcripts & Audio
$2.30
-0.02 (-0.86%)
At close · Nov 16
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$295.50M
Shares
127.37M
Volume · Nov 16
1.74M
Avg daily vol (3M)
5.87M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Nautilus Biotechnology, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Nautilus Biotechnology, Inc. (NAUT), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-10-27
Nautilus Biotechnology, Inc. (NAUT) Q3 2026 Earnings Call Transcript
Confident tone
Collaborations and grant funding
Commercial launch timeline
Proteoform platform differentiation
Revenue
$234,000
Diluted EPS
$-0.12
Gross margin
89.7%
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2026-07-28
Nautilus Biotechnology, Inc. (NAUT) Q2 2026 Earnings Call Transcript
Positive tone
Broad scale program delays
Strategic pivot to Proteoform
Oncology expansion and sample types
Revenue
$190,000
Diluted EPS
$-0.11
Gross margin
92.1%
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-04-28
Nautilus Biotechnology, Inc. (NAUT) Q1 2026 Earnings Call Transcript
Confident tone
Commercialization and customer engagement
Voyager platform and broad-scale assay development
Oncology proteoform target
Diluted EPS
$-0.12
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Nautilus Biotechnology, Inc. (NAUT) Q4 2025 Earnings Call Transcript
Confident tone
Voyager instrument unveiling and early access program
Proteomics platform and proteoform diversity
Tau proteoform assay and collaborations
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-28
Nautilus Biotechnology, Inc. (NAUT) Q3 2025 Earnings Call Transcript
Confident tone
Tau proteoform assay and collaborations
Broad-scale assay configuration / technology development
Operational discipline and spending / runway
Revenue
$0
Diluted EPS
$-0.11
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
Nautilus Biotechnology, Inc. (NAUT) Q2 2025 Earnings Call Transcript
Confident tone
Customer engagement and collaborations
Tau proteoform manuscript and scientific validation
Platform reproducibility and performance
Revenue
$0
Diluted EPS
$-0.12
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-04-29
Nautilus Biotechnology, Inc. (NAUT) Q1 2025 Earnings Call Transcript
Confident tone
Tau Proteoform Assay V&V
Broad Scale Proteome / Platform Development
Customer and Partnership Interest
Diluted EPS
$-0.13
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Nautilus Biotechnology, Inc. (NAUT) Q4 2024 Earnings Call Transcript
Positive tone
Broadscale discovery
Tau proteoform assay
Probe optimization
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-29
Nautilus Biotechnology, Inc. (NAUT) Q3 2024 Earnings Call Transcript
Cautious tone
Proteoform data and modality progress
Broad scale protein quantification milestone
Proteomics market opportunity
Diluted EPS
$-0.13
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-07-30
Nautilus Biotechnology, Inc. (NAUT) Q2 2024 Earnings Call Transcript
Positive tone
Proteoform Technology
Platform Development Metrics
Product Launch Timeline
Diluted EPS
$-0.14
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-30
Nautilus Biotechnology, Inc. (NAUT) Q1 2024 Earnings Call Transcript
Confident tone
U.S. HUPO conference reception
Supply chain and manufacturing readiness
Key opinion leader and researcher engagement
Diluted EPS
$-0.15
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Nautilus Biotechnology, Inc. (NAUT) Q4 2023 Earnings Call Transcript
Positive tone
Platform Launch Timeline
R&D Progress and Reproducibility
Single-Molecule Protein Decoding
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-31
Nautilus Biotechnology, Inc. (NAUT) Q3 2023 Earnings Call Transcript
Diluted EPS
$-0.13
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
Nautilus Biotechnology, Inc. (NAUT) Q2 2023 Earnings Call Transcript
Diluted EPS
$-0.13
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-02
Nautilus Biotechnology, Inc. (NAUT) Q1 2023 Earnings Call Transcript
Diluted EPS
$-0.12
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-23
Nautilus Biotechnology, Inc. (NAUT) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-01
Nautilus Biotechnology, Inc. (NAUT) Q3 2022 Earnings Call Transcript
Diluted EPS
$-0.11
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-02
Nautilus Biotechnology, Inc. (NAUT) Q2 2022 Earnings Call Transcript
Diluted EPS
$-0.12
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Nautilus Biotechnology, Inc. (NAUT) Q1 2022 Earnings Call Transcript
Diluted EPS
$-0.13
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Nautilus Biotechnology, Inc. (NAUT) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Nautilus Biotechnology, Inc. (NAUT) Q3 2021 Earnings Call Transcript
Diluted EPS
$-0.12
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-10
Nautilus Biotechnology, Inc. (NAUT) Q2 2021 Earnings Call Transcript
Diluted EPS
$-0.19
Audio
Transcript
Slides
8-K10-Q
Showing 1–22 of 22 webcasts
Key facts
CIK
1808805
CUSIP
63909J108
13F (30d)
65 filings
54 filers
Visit website
Investor relations